Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 503 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non-fasting Clear all

Conditions: Insulin Resistance, Prediabetic State, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease, Obesity
Interventions: Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, CORE Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer; Drug · Other · Dietary Supplement + 1 more
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: MF-300 SAD, Placebo, MF-300 Food Effect, MF-300 MAD; Drug
Lead sponsor: Epirium Bio Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Marlton, New Jersey • Austin, Texas

Conditions: Food Selection
Interventions: Control (QR) Labels, Low Environmental Harm Labels, High Environmental Harm Labels, Environmental Harm Traffic Light Labels, Environmental Grade Labels; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stage IV NSCLC, NSCLC, Immunotherapy, Fasting Mimicking Diet
Interventions: FMD, Regular Diet Plus FMD; Dietary Supplement · Combination Product
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 4
States / cities: Long Beach, California • Chicago, Illinois • Indianapolis, Indiana + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, Liraglutide, Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 45
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more

Conditions: Healthy
Interventions: divalproex sodium, Depakote®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Hiv, Diabetes Mellitus, Type 2
Interventions: Subcutaneous adipose tissue biopsy, CT scan, Oral glucose tolerance test, Blood collection; Procedure · Radiation · Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cancer
Interventions: Ixabepilone, 5 mg/d, Ixabepilone, 10 mg/d, Ixabepilone, 15 mg/d, Ixabepilone, 20 mg/d, Ixabepilone, 25 mg/d, Ixabepilone, 30 mg/d, Ixabepilone, 25 mg, with famotidine, Ixabepilone, 25 mg, with food; Drug
Lead sponsor: R-Pharm; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Detroit, Michigan

Conditions: Osteonecrosis
Interventions: Functional Mobility Assessment, GAITRite® System, Range of Motion; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 8 Years to 29 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Peripheral Artery Disease (PAD), Ischemia, Intermittent Claudication
Interventions: Chocolate Touch, Lutonix Drug Coated Balloon; Device
Lead sponsor: TriReme Medical, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 15
States / cities: Gainesville, Florida • Miami Beach, Florida • Atlanta, Georgia + 11 more

Conditions: Spinal Cord Injury, Obesity
Interventions: Time Restricted Eating; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Hepatic Impairment
Interventions: Nalbuphine ER; Drug
Lead sponsor: Trevi Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida

Conditions: Human Immunodeficiency Virus, Metabolic Syndrome
Interventions: Intermittent fasting, Standard of Care; Behavioral · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity
Interventions: Eucalaloric feeding, Acute Fasting, Acute Overfeeding; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Non-small Cell Lung Cancer
Interventions: Fasting-Mimicking Diet; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Indianapolis, Indiana

Conditions: Obesity, Diabetes Mellitus, Type 2, Appetitive Behavior
Interventions: Isomaltooligosaccharides (IMOs), Xtend® sucromalt, Combination of IMOs and Xtend® sucromalt, Raw corn starch, Maltodextrin; Other
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Stroke
Interventions: Propulsion Neuroprosthesis; Device
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Famciclovir 500 mg Tablets, Famvir® 500 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Improving Cardiometabolic Outcomes in Adults
Interventions: Melatonin 1 mg, Placebos, Meal Timing, NON Meal Timing; Dietary Supplement · Other
Lead sponsor: Northwestern University; Other
Eligibility: 35 Years to 54 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hip Fracture
Interventions: Nutrition, PUSH, PULSE; Dietary Supplement · Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 60 Years and older
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: Farmington, Connecticut • Baltimore, Maryland • Lebanon, New Hampshire + 1 more

Conditions: Neoplasms
Interventions: Regorafenib (BAY73-4506) + rifampin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Obesity
Interventions: Oral Glucose Tolerance Test (OGTT), Assessment of dietary compliance, Stool sampling, Sodium Saccharin, Placebo, Lactisole; Other
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 45 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Intermittent Fasting
Interventions: Intermittent Fasting; Behavioral
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 21 Years to 70 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Hyperlipidemia, Pregnancy
Interventions: Lipid panel; Diagnostic Test
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Pancreatic Clamp in NAFLD

Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants

Testing Non-Nutrition Menu Labels on Food Selections

Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions

The HIV, Adipose Tissue Immunology, and Metabolism Study

A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer

Functional Outcomes Following Hip Core Decompression in Younger Participants With Osteonecrosis

The Chocolate Touch Study

Time Restricted Eating to Mitigate Obesity in Veterans With Spinal Cord Injury

Study of Nalbuphine ER in Participants With Hepatic Impairment

2-5 Intermittent Caloric Restriction in HIV

Thermogenenic Responses to Fasting and Overfeeding in Women

Fasting-mimicking Diet With Chemo-immunotherapy in Non-small Cell Lung Cancer (NSCLC)

Slowly Digestible Carbohydrates and the Ileal Brake

Effects of an Overground Propulsion Neuroprosthesis in Community-dwelling Individuals After Stroke

Famciclovir 500 mg Tablets Under Non-Fasting Conditions

Strengthening Circadian Signals

Improving Community Ambulation After Hip Fracture

Effect of Rifampin on the Pharmacokinetics of BAY73-4506

Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors

Weekly ONe-Day WatER-only Fasting InterventionaL Trial for Low-Density Lipoprotein Cholesterol Reduction

Lipid Profile as Predictor of Adverse Maternal and Neonatal Outcomes: A Pilot Study